* Adaptive Biotechnologies Corp is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2024
* The Seattle Washington-based company is expected to report a 3.0% increase in revenue to $38.784 million from $37.65 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Adaptive Biotechnologies Corp is for a loss of 34 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 10.4% in the last three months.
* Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $5.00, above its last closing price of $3.01.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.33 -0.33 -0.30 Beat 9.4
Sep. 30 2023 -0.35 -0.34 -0.35 Missed -3.3
Jun. 30 2023 -0.35 -0.35 -0.33 Beat 4.8
Mar. 31 2023 -0.37 -0.38 -0.40 Missed -6.2
Dec. -0.34 -0.35 -0.28 Beat 19.2
31 2022
Sep. 30 2022 -0.37 -0.38 -0.32 Beat 14.9
Jun. 30 2022 -0.41 -0.43 -0.37 Beat 14
Mar. 31 2022 -0.45 -0.46 -0.44 Beat 4.1
This summary was machine generated May 4 at 02:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments